BioArctic Stock

BioArctic Cash Flow per Share

The Operating Cash Flow per Share of BioArctic (BIOA B.ST) as of Aug 24, 2026 is 16.13 SEK. In the previous year, Operating Cash Flow per Share was -3.58 SEK — a change of -550.37% (higher).

Cash Flow per Share

16.13SEK

YoY

-550.37%

Last updated:

Operating Cash Flow per Share of BioArctic is 2026 16.13 SEK. Operating Cash Flow per Share of BioArctic was 2025 -3.58 SEK. It decreases by -550.37% higher compared to the previous year.

The BioArctic Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
-2.27 SEK
Jan 1, 2019
3.72 SEK
Jan 1, 2020
-1.05 SEK
Jan 1, 2021
-1.60 SEK
Jan 1, 2022
-0.37 SEK
Jan 1, 2023
3.50 SEK
Jan 1, 2024
-3.58 SEK
Jan 1, 2025
16.13 SEK
The BioArctic Cash Flow per Share history
YEARCash Flow per ShareYoY
16.13SEK-550.37%
-3.58SEK-202.31%
3.50SEK-1,051.27%
-0.37SEK-76.93%
-1.60SEK+52.11%
-1.05SEK-128.22%
3.72SEK-263.67%
-2.27SEK+14.17%
-1.99SEK-118.57%
10.71SEK-5,836.80%
-0.19SEK
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Operating Cash Flow per Share of BioArctic is 16.13 SEK in 2026.

Operating Cash Flow per Share of BioArctic changed from -3.58 SEK to 16.13 SEK, representing a -550.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share BioArctic since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

Cash Flow — BioArctic

All Key Metrics — BioArctic